Endo International plc (ENDP)
(Delayed Data from NSDQ)
$8.20 USD
+0.48 (6.22%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.19 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.20 USD
+0.48 (6.22%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.19 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Pacira's (PCRX) Q3 Earnings Beat Estimates, Revenues Miss Mark
by Zacks Equity Research
Pacira's (PCRX) earnings beat estimates in the third quarter of 2021 while revenues miss the same. Its flagship product Exparel's sales rise year over year.
Drug, Biotech Stock Q3 Earnings on Nov 4: MRNA, REGN & More
by Zacks Equity Research
Let us take a look at five drug/biotech companies due to release their quarterly results on Nov 4.
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis (ZTS) is set to report earnings and revenues, and provide updates on its diversified product portfolio when it releases third-quarter 2021 results.
Endo International (ENDP) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Endo (ENDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why the Earnings Surprise Streak Could Continue for Endo (ENDP)
by Zacks Equity Research
Endo (ENDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Endo (ENDP) Gains on Settlement of Opioid Cases in New York for $50M
by Zacks Equity Research
Endo (ENDP) stock gains following the settlement of three opioid cases in the New York State in exchange for a total payment of $50 million.
BioMarin (BMRN) Phenylketonuria Gene Therapy on Clinical Hold
by Zacks Equity Research
BioMarin's (BMRN) phase I/II study on gene therapy candidate, BMN 307, has been placed under a clinical hold by the FDA possibly on malignancy concerns.
Are Options Traders Betting on a Big Move in Endo International (ENDP) Stock?
by Zacks Equity Research
Investors need to pay close attention to Endo International (ENDP) stock based on the movements in the options market lately.
Endo International (ENDP) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Endo (ENDP) delivered earnings and revenue surprises of 54.76% and 8.61%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Endo International (ENDP) Q2 Earnings Expected to Decline
by Zacks Equity Research
Endo (ENDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Endo International (ENDP) Stock?
by Zacks Equity Research
Investors need to pay close attention to Endo International (ENDP) stock based on the movements in the options market lately.
Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q1
by Zacks Equity Research
Endo's (ENDP) earnings and sales beat estimates in the first quarter, driven by revived demand.
Endo International (ENDP) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Endo (ENDP) delivered earnings and revenue surprises of 52.08% and 7.08%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Endo International (ENDP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Endo (ENDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why the Earnings Surprise Streak Could Continue for Endo (ENDP)
by Zacks Equity Research
Endo (ENDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Is Endo (ENDP) Down 16.8% Since Last Earnings Report?
by Zacks Equity Research
Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q4
by Zacks Equity Research
Endo's (ENDP) earnings and sales beat estimates in the fourth quarter.
Radius' (RDUS) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Radius (RDUS) reports a wider loss but beats sales estimates in the fourth quarter.
Can Endo (ENDP) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Endo (ENDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why Momentum Investors Will Love Endo International (ENDP)
by Zacks Equity Research
Does Endo International (ENDP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Radius (RDUS) to Acquire Rights for Cannabidiol Oral Solution
by Zacks Equity Research
Radius (RDUS) is set to acquire the global development and commercialization rights of Benuvia Therapeutics' synthetic cannabidiol oral solution for utilization in multiple endocrine and metabolic orphan diseases.
Radius (RDUS) Inks Deal for Tymlos in Canada With Paladin Labs
by Zacks Equity Research
Radius (RDUS) signs an agreement with Paladin Labs, wherein the latter will now be responsible for all commercial activities related to Tymlos and abaloparatide-TD in Canada.
Why Is Endo (ENDP) Up 10.5% Since Last Earnings Report?
by Zacks Equity Research
Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Can Value Investors Pick Endo International (ENDP) Stock ?
by Zacks Equity Research
Is Endo International (ENDP) a great pick from the value investor's perspective right now? Read on to know more.
Endo (ENDP) Q3 Earnings & Sales Top Estimates, View Raised
by Zacks Equity Research
Endo's (ENDP) earnings and sales beat estimates in the third quarter. The company raises its annual outlook.